Centessa Pharmaceuticals PLC ADR

10-Year Study

CNTA.US · Healthcare · US · Common Stock

Executive Summary: Centessa Pharmaceuticals PLC ADR has compounded at 12.9% annually over the last 10 years, with a maximum drawdown of 86.0% and an annualized volatility of 134.2%.

1Y CAGR
+222.4%
3Y CAGR
+110.4%
5Y CAGR
+12.9%
10Y CAGR
+12.9%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
86.0%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.51
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.88
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
62.5%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2023 · +156.8%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2022 · -72.5%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
80%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-1.89.347.9-0.5————————58.1%
20251.0-8.1-7.5-4.7-1.5-2.730.7-2.244.42.716.6-13.849.3%
20242.928.37.5-18.9-5.84.616.628.218.4-5.919.1-6.5110.4%
202329.0-12.09.422.6-4.437.327.6-4.6-14.21.5-8.732.7156.8%
2022-15.4-6.40.6-2.8-48.48.2-11.30.7-7.6-1.20.8-22.5-72.5%
2021—————2.1-7.16.8-24.33.0-31.1-5.0-48.2%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 134.2%. The dominant macroeconomic risk driver is SHV.US, accounting for 70.7% of variance. Idiosyncratic stock-specific factors contribute 12.2%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2021-05-0110000
2021-06-0110211.494252873563
2021-07-019489.655172413793
2021-08-0110137.931034482759
2021-09-017678.16091954023
2021-10-017908.045977011494
2021-11-015448.275862068966
2021-12-015177.0114942528735
2022-01-014381.609195402299
2022-02-014101.149425287356
2022-03-014124.137931034483
2022-04-014009.1954022988507
2022-05-012068.965517241379
2022-06-012239.080459770115
2022-07-011986.2068965517244
2022-08-011999.9999999999998
2022-09-011848.2758620689654
2022-10-011825.287356321839
2022-11-011839.0804597701149
2022-12-011425.287356321839
2023-01-011839.0804597701149
2023-02-011618.3908045977012
2023-03-011770.1149425287358
2023-04-012170.1149425287354
2023-05-012073.5632183908046
2023-06-012845.977011494253
2023-07-013632.183908045977
2023-08-013466.666666666667
2023-09-012974.7126436781605
2023-10-013020.689655172414
2023-11-012758.6206896551726
2023-12-013659.770114942529
2024-01-013765.5172413793102
2024-02-014832.183908045977
2024-03-015195.402298850576
2024-04-014211.494252873564
2024-05-013967.8160919540232
2024-06-014151.724137931034
2024-07-014841.379310344827
2024-08-016206.896551724138
2024-09-017351.724137931035
2024-10-016914.942528735632
2024-11-018234.482758620688
2024-12-017701.149425287355
2025-01-017779.310344827587
2025-02-017149.425287356323
2025-03-016611.494252873563
2025-04-016303.448275862069
2025-05-016211.494252873563
2025-06-016041.379310344828
2025-07-017894.252873563219
2025-08-017719.540229885057
2025-09-0111149.425287356322
2025-10-0111448.275862068964
2025-11-0113347.12643678161
2025-12-0111498.850574712644
2026-01-0111296.551724137931
2026-02-0112349.425287356322
2026-03-0118262.068965517243
2026-04-0118174.712643678162
Annual Return Matrix
YearAnnual Return
2022-0.7246891651865008
20231.567741935483871
20241.1042713567839195
20250.49313432835820903
20260.5805677728908436
Total Factor Risk
1.3423095389411537
VTI.US Exposure
0.08366323560498015
VEA.US Exposure
-0.0027912253260942263
VWO.US Exposure
0.01032622574527466
QQQ.US Exposure
-0.01418197811286692
VTV.US Exposure
-0.004616838257383466
IJR.US Exposure
-0.007865695948713471
QUAL.US Exposure
-0.004549493399482013
SHV.US Exposure
0.707280021782183
TLT.US Exposure
0.050898468549872386
LQD.US Exposure
0.023150829664735962
HYG.US Exposure
0.006643664990660682
GLD.US Exposure
0.0015908180221757841
USO.US Exposure
0.0006603781076246972
VNQ.US Exposure
0.02399985428385739
BTC-USD.CC Exposure
0.0012264681601481522
CPER.US Exposure
-0.0006207573683095708
VIX.INDX Exposure
0.0002538715172202822
UUP.US Exposure
0.00021124458441330326
TIP.US Exposure
0.00298392634689065
Idiosyncratic Exposure
0.12173698105281261
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
134.2%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$6.1B
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+34.0%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+66.3%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
0.8% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.55
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Centessa Pharmaceuticals PLC ADR a high-risk investment?

Centessa Pharmaceuticals PLC ADR (CNTA.US) has an annualized volatility of 134.2% and experienced a maximum drawdown of 86.0% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of CNTA.US?

Over the past 10 years, CNTA.US has generated a Compound Annual Growth Rate (CAGR) of 12.9%. It has had a positive return in 80% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Centessa Pharmaceuticals PLC ADR

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest